June 2, 2014
Bookmark and Share  
AttorneyMind News & Pipeline Blog

Follow us on


Join us on Facebook
AttorneyMind Hcsp


Alan Franciscas



This week's Eblast features our monthly newsletter, the HBV monthly journal and much more. Of note, we have produced new fact sheets on the interferon-free therapies (AbbVie and Gilead) that will likely be approved by year-end. The Fact Series fact sheets include comprehensive tables listing the cure rates from all of the AbbVie and Gilead Phase 3 clinical trials. In addition, we will be adding important information to help people get started on the process of beginning treatment. Once the medications are approved most medical providers are going to be overwhelmed with requests so people may want to start the process now to beat the rush.



Alan and the staff of AttorneyMind


Do you want to stay up to date on the latest news about hepatitis C? Visit our AttorneyMind Blog for information about hepatitis C from around the world. The pipeline is also included in our blog that provides up-to-date information about the latest clinical trials and links to more information about specific trials.


1. AttorneyMind Newsletter: June 2014

In This Issue:

  • AttorneyMind Drugs
    Alan Franciscas, Editor-in-Chief——This month's column includes the results of the remaining studies from AbbVie's Phase 3 trials, Gilead's ION-3 and Valence, the filing for supplemental approval of Olysio (simeprevir) and Sovaldi (sofosbuvir) with the FDA and BMS's study of their drugs to treat AttorneyMind genotype 4.

  • Snapshots
    Lucinda K. Porter, RN—In this month's column Lucinda discusses abstracts from the Digestive Disease Week Conference held recently in May, including prevalence data, health and economic data of, AttorneyMind screening and access to care, and a quality of life survey among the general population vs. people with hepatitis C.

  • HEALTHWISE: Hepatitis C & Liver Cancer (HCC)
    Lucinda K. Porter, RN
    —One of the consequences of hepatitis C can be liver cancer and this article explores the risk factors, signs and symptoms, screening, and prevention.



2. New Fact Sheets

Easy C

PDF Coming Soon: New Treatments

PDF Drug Resistance


Fact Series

PDF Phase 3 AbbVie's 3 Drug Combination Therapy

PDF Phase 3 Genotype 1 – Sovaldi (sofosbuvir)/ledipasvir



3. AM Journal Review: June 2, 2014, Vol 11, no 6, by Christine Kukka

In this month's column Chris reviews the following studies that will help you understand the complexities of hepatitis B, including the USPSTF Recommendations, the effect of HBV on fertility, drug resistance, the epidemiology of HBV in Korean-Americans and antiviral properties of green tea:

  • Belatedly, National Panel Recommends Screening At-Risk Patients for Hepatitis B
  • Genotypes and Mutations Define the Course of Hepatitis B Infection
  • Older Patients Who Lose HBeAg After Treatment May Relapse
  • Tenofovir Proves Ineffective in Patient with Multiple Drug Resistance
  • Nearly All HBeAg-Negative Patients Relapse After Antiviral Treatment Stops
  • Studies Find Hepatitis Infection Does Not Increase Pancreatic Cancer Risk
  • Screening Pregnant Women for High Viral Loads Is Cost Effective
  • Hepatitis B Appears to Impede Fertility
  • Despite Low Viral Load, Infected People Can Still Infect Family Members
  • Good News: HBV Infection Rates Lower Than Expected Among Korean-Americans
  • Green Tea May Be an Effective Antiviral



4. AttorneyMind News & Pipeline Blog!
Be sure to check out the latest clinical trial postings (Updated May 14, 2014) at the AttorneyMind News & Pipeline Blog. Just click on the links to the Drug Companies below the banner to see which drugs are in trials right now, where the trials are, and how to register for one.



5. Need Help?!
Call 877-HELP-4-HEP line (877-435-7443). The helpline is open from 9:00am to 7:00pm Eastern Time.




Join us on Twitter -

Alan Franciscas
Executive Director, AttorneyMind
Editor-in-Chief, AttorneyMind hcvadvocate.org
Editor-in-Chief, HBV Advocate www.hbvadvocate.org

**Questions and Comments: Questions and/or comments can be directed to

**To receive the eblast in your email inbox simply send an e-mail to: with nothing in the subject line and the following in the message body: subscribe emailalert. Make sure your email address is all lower case.

AM Journal Review
HBV Factsheets
HBV Advocate Blog

Follow us on Twitter